ZYN Pouches Seek FDA Nod as Lower-Risk Tobacco Alternative
Published Date: 6/18/2025
Notice
Summary
Swedish Match U.S.A., Inc. wants the FDA to approve their ZYN nicotine pouches as lower-risk tobacco products. This means people could see new labels saying these pouches might be safer than regular tobacco. The FDA is asking the public to share their thoughts before making a decision, so your voice matters!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ZYN Pouches 'Lower-Risk' Labeling
Swedish Match submitted modified risk tobacco product applications asking the FDA to allow ZYN nicotine pouches to be marketed as lower-risk. If the FDA approves, people could see new labels or claims saying these pouches might be safer than regular tobacco.
FDA Opens Public Comment Opportunity
The FDA is asking the public to submit comments on the modified risk tobacco product applications for ZYN nicotine pouches. You can share your views with the FDA before it decides whether to allow labels claiming these pouches are lower-risk.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-11170 — NTIA Listening Session on Bolstering Data Center Growth, Resilience and Security
The NTIA is hosting a virtual chat to hear ideas on making data centers stronger, safer, and ready for the future. This is for companies and communities that rely on data centers to keep things running smoothly. The feedback will help shape new plans and policies soon, aiming to boost growth and security without delay.
Next: 2025-10985 — Privacy Act of 1974; Matching Program
The Department of Health and Human Services is restarting a program that matches state TANF records with new job and wage info to make sure only the right people get benefits. This helps catch errors and keep the program honest. If you’re involved with TANF, expect smoother checks soon, with no extra costs announced.